LB Pharmaceuticals
LBRX | NASDAQ
$42.99
-$0.02 (-0.05%)
At close: Nov 16, 2026, 4:00 PM ET
$42.99
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
LB Pharmaceuticals Company Profile
Company profile explainedCompany Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Key Executives
| Name | Position |
|---|---|
| Heather D. Turner | Chief Executive Officer & Director |
| Joseph Miller | Chief Financial Officer |
| Anna Eramo | Advisor |
| Christopher Zergebel | Senior Vice President of Clinical Operations |
| Ellen Rose | Senior Vice President of Corporate Affairs |
| James Rawls | Senior Vice President of Regulatory Affairs |
| Kaya Pai Panandiker | Chief Commercial Officer |
| Lindsay Beaupre | Senior VP of People & Culture |
| Marc L. Panoff | Senior Vice President of Finance |
| Minako Pazdera | General Counsel |
| Richard Silva | Senior Vice President of Technical Operations |
| Soffer | Chief Operating & Business Officer |
| Susan G. Kozauer | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 05, 2026 | EFFECT | Filing |
| Oct 01, 2026 | POS AM | Filing |
| Oct 01, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Sep 24, 2026 | 3 | Filing |
| Sep 15, 2026 | 424B3 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 3 | Filing |
LB Pharmaceuticals
| Country | United States |
| IPO Date | Sep 11, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Heather D. Turner |
Contact Details
One Pennsylvania Plaza New York,
New York 10119 United States
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001691082 |
| CUSIP Number | 50180M108 |
| ISIN Number | US50180M1080 |
| SIC Code | 2834 |
Recent News
- 20 days ago / marketbeat.comLB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
- 1 month ago / globenewswire.comLB Pharmaceuticals to Participate in Upcoming Investor Events
- 2 months ago / seekingalpha.comLB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
- 2 months ago / globenewswire.comLB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
- 2 months ago / globenewswire.comLB Pharmaceuticals to Participate in Upcoming September Investor Events
- 4 months ago / globenewswire.comLB Pharmaceuticals Announces $150 Million Private Placement
Add to Watchlist
Select watchlists to add or remove LBRX